Switch theme
Sign up to access all valuation multiples
Blueprint Medicines Corp is a biopharmaceutical company. It is developing medicines in the following focus areas; allergy, inflammation, oncology, and hematology. Its approved medicines, including Avyakit and Avyakyt, are given to patients living with systemic mastocytosis (SM) and PDGFRA Exon 18 mutant GIST in the U.S. and Europe. The company also has various other drug candidates in its pipeline such as BLU-808, BLU-222, BLU-956, and others that are being developed to treat mast cell diseases including SM and chronic urticaria, breast cancer, and other solid tumors. Geographically, it operates in the United States, which is its key revenue market, and Europe.
2008
649
LTM Revenue $578M
LTM EBITDA -$136M
$5.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Blueprint Medicines has a last 12-month revenue of $578M and a last 12-month EBITDA of -$136M.
In the most recent fiscal year, Blueprint Medicines achieved revenue of $509M and an EBITDA of $19.2M.
Blueprint Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Blueprint Medicines valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $249M | $509M | XXX | XXX | XXX |
| Gross Profit | $186M | $241M | XXX | XXX | XXX |
| Gross Margin | 75% | 47% | XXX | XXX | XXX |
| EBITDA | -$470M | $19.2M | XXX | XXX | XXX |
| EBITDA Margin | -189% | 4% | XXX | XXX | XXX |
| Net Profit | -$558M | -$507M | XXX | XXX | XXX |
| Net Margin | -224% | -100% | XXX | XXX | XXX |
| Net Debt | $19.4M | $168M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 28, 2025, Blueprint Medicines's stock price is $88.
Blueprint Medicines has current market cap of $5.6B, and EV of $5.5B.
See Blueprint Medicines trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.5B | $5.6B | XXX | XXX | XXX | XXX | $-1.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 28, 2025, Blueprint Medicines has market cap of $5.6B and EV of $5.5B.
Blueprint Medicines's trades at 9.4x LTM EV/Revenue multiple, and -40.2x LTM EBITDA.
Analysts estimate Blueprint Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Blueprint Medicines and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $5.5B | XXX | XXX | XXX |
| EV/Revenue | 10.7x | XXX | XXX | XXX |
| EV/EBITDA | 283.6x | XXX | XXX | XXX |
| P/E | -83.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -27.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpBlueprint Medicines's NTM/LTM revenue growth is 38%
Blueprint Medicines's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $1.1M for the same period.
Over next 12 months, Blueprint Medicines's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Blueprint Medicines's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Blueprint Medicines and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 104% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 4% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -104% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 41% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 19% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 52% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 67% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 138% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Blueprint Medicines acquired XXX companies to date.
Last acquisition by Blueprint Medicines was XXXXXXXX, XXXXX XXXXX XXXXXX . Blueprint Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Blueprint Medicines founded? | Blueprint Medicines was founded in 2008. |
| Where is Blueprint Medicines headquartered? | Blueprint Medicines is headquartered in United States of America. |
| How many employees does Blueprint Medicines have? | As of today, Blueprint Medicines has 649 employees. |
| Who is the CEO of Blueprint Medicines? | Blueprint Medicines's CEO is Ms. Kathryn Haviland. |
| Is Blueprint Medicines publicy listed? | Yes, Blueprint Medicines is a public company listed on NAS. |
| What is the stock symbol of Blueprint Medicines? | Blueprint Medicines trades under BPMC ticker. |
| When did Blueprint Medicines go public? | Blueprint Medicines went public in 2015. |
| Who are competitors of Blueprint Medicines? | Similar companies to Blueprint Medicines include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Blueprint Medicines? | Blueprint Medicines's current market cap is $5.6B |
| What is the current revenue of Blueprint Medicines? | Blueprint Medicines's last 12-month revenue is $578M. |
| What is the current EBITDA of Blueprint Medicines? | Blueprint Medicines's last 12-month EBITDA is -$136M. |
| What is the current EV/Revenue multiple of Blueprint Medicines? | Current revenue multiple of Blueprint Medicines is 9.4x. |
| What is the current EV/EBITDA multiple of Blueprint Medicines? | Current EBITDA multiple of Blueprint Medicines is -40.2x. |
| What is the current revenue growth of Blueprint Medicines? | Blueprint Medicines revenue growth between 2023 and 2024 was 104%. |
| Is Blueprint Medicines profitable? | Yes, Blueprint Medicines is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
